<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02585934</url>
  </required_header>
  <id_info>
    <org_study_id>RVT-101-3001</org_study_id>
    <nct_id>NCT02585934</nct_id>
  </id_info>
  <brief_title>Study Evaluating Intepirdine (RVT-101) in Subjects With Mild to Moderate Alzheimer's Disease on Donepezil: MINDSET Study</brief_title>
  <official_title>A Phase 3, Double-blind, Randomized Study of RVT-101 Versus Placebo When Added to Existing Stable Donepezil Treatment in Subjects With Mild to Moderate Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Axovant Sciences Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Axovant Sciences Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to confirm a demonstrated treatment effect of intepirdine (RVT-101) as an
      adjunctive therapy to donepezil for the treatment of subjects with Alzheimer's disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase 3 study seeks to confirm a demonstrated treatment effect of intepirdine (RVT-101)
      on both cognition and activities of daily living when added to stable donepezil treatment in
      subjects with mild-to-moderate Alzheimer's disease after 24 weeks of double-blind treatment.
      This study will also provide further information on the safety and tolerability of the 35-mg
      dose of intepirdine (RVT-101) when used in combination with donepezil compared to donepezil
      alone. This study is being conducted under the agreement of a Special Protocol Assessment by
      FDA. Subjects completing this study will be eligible to enroll in a 12 month open-label study
      of RVT-101 (RVT-101-3002) in which concomitant medications for the treatment of Alzheimer's
      disease including memantine will be allowed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2015</start_date>
  <completion_date type="Actual">September 2017</completion_date>
  <primary_completion_date type="Actual">September 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alzheimer's Disease Assessment Scale - Cognitive Subscale 11 Items (ADAS-Cog-11) Score Change From Baseline to Week 24</measure>
    <time_frame>Baseline, 24 weeks</time_frame>
    <description>The 11-item ADAS-Cog assesses a range of cognitive abilities including memory, comprehension, orientation in time and place, and spontaneous speech. The ADAS-Cog-11 total score range is from 0 to 70, with a higher score indicating more severe cognitive impairment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) Score Change From Baseline to Week 24</measure>
    <time_frame>Baseline, 24 weeks</time_frame>
    <description>The ADCS-ADL scale measures functional impairment in terms of activities of daily living. The score ranges from 0 to 78. The lower the score, the greater the impairment; higher scores indicate better (more desirable) function</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of Change - Plus Caregiver Interview (CIBIC+) Score at Week 24</measure>
    <time_frame>24 weeks</time_frame>
    <description>The CIBIC+ assessment measures the global functioning of the subject. The CIBIC+ is scored as a seven-point categorical rating, ranging from a score of 1 (indicating &quot;very much improved&quot;), to a score of 4 (indicating &quot;no change&quot;), or to a score of 7 (indicating &quot;very much worse.&quot;) Lower CIBIC+ scores indicate better (more desirable) function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Dependence Scale (DS) Score Change From Baseline to Week 24</measure>
    <time_frame>Baseline, 24 weeks</time_frame>
    <description>The DS measures the amount of assistance patients with dementia require in performing daily activities. The scale consists of 13 items, representing a range of severity from mild to severe levels of dependency. The score range is from 0 to 15 with higher scores indicating greater dependency.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychiatric Inventory (NPI) Score Change From Baseline to Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>The NPI is a behavior rating scale composed of a 12-item structured interview of the caregiver that is scored from 0 to 144 (the higher the score, the greater the psychiatric disturbance). It assesses 12 behavioral disturbances occurring in dementia patients: delusions, hallucinations, agitation, dysphoria, anxiety, apathy, irritability, euphoria, disinhibition, aberrant motor activity, night-time behavior disturbances, and eating disturbances. Both the frequency and the severity of each behavior are determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADAS-Cog-13 Score Change From Baseline to Week 24</measure>
    <time_frame>Baseline, 24 weeks</time_frame>
    <description>13-item ADAS-Cog assesses a range of cognitive abilities including memory, comprehension, orientation in time and place, and spontaneous speech. Most items are evaluated by tests, but some are dependent on clinician ratings on a 5-point scale. The ADAS-Cog-13 is the ADAS-Cog-11 with 2 additional items: delayed word recall and total digit cancellation. Scores for the ADAS-Cog-13 range from 0 to 85 with higher scores indicating greater dysfunction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of Concentrations of RVT-101 (Intepirdine) in Plasma</measure>
    <time_frame>Week 6, Week 12, Week 18, Week 24</time_frame>
    <description>Measurement collected at timepoints Week 6, Week 12, Week 18, and Week 24</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1315</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>RVT-101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RVT-101 adjunct to 5 mg or 10 mg donepezil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo adjunct to 5 mg or 10 mg donepezil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RVT-101</intervention_name>
    <description>once daily, oral, 35 mg tablets</description>
    <arm_group_label>RVT-101</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>once daily, oral, pill manufactured to match RVT-101 35 mg tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subject with AD

          -  Ongoing donepezil therapy for AD

          -  An MMSE score 12 to 24 inclusive at Screening; MMSE score 10-26 inclusive at Baseline

          -  Hachinski Ischaemia score less than or equal to 4 at Screening.

          -  If female, subject must be: a. of non-childbearing potential or surgically sterile;
             or, b. willing to use an adequate methods of birth control. Male subjects who are
             sexually active will also be required to use an adequate form of birth control.

          -  Subject has the ability to comply with procedures for cognitive and other testing in
             the opinion of the investigator.

          -  Subject has a reliable caregiver who is willing to report on subject's status
             throughout the study.

        Exclusion Criteria:

        Other Causes for Dementia

          -  Diagnosis of vascular dementia

          -  Atypical clinical features or clinical course of dementia that would lead the
             investigator to conclude symptoms are more likely due to an alternate dementia
             diagnosis including, but not limited to, frontotemporal dementia, Lewy body dementia,
             or others.

        Confounding Medical Conditions

          -  History of significant psychiatric illness such as schizophrenia or bipolar affective
             disorder or any other significant psychiatric illness that in the opinion of the
             investigator would interfere with participation in the study;

          -  Any clinically relevant concomitant disease, which, in the opinion of the
             investigator, makes the subject unsuitable for inclusion in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ilise Lombardo, MD</last_name>
    <role>Study Director</role>
    <affiliation>Axovant Sciences, Inc., Vice President, Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>US112</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US220</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US168</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91436</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US117</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US214</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US189</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US096</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <zip>92270</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US0195</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US016</name>
      <address>
        <city>Simi Valley</city>
        <state>California</state>
        <zip>93065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US106</name>
      <address>
        <city>Temecula</city>
        <state>California</state>
        <zip>92591</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US179</name>
      <address>
        <city>Hamden</city>
        <state>Connecticut</state>
        <zip>06518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US171</name>
      <address>
        <city>Norwich</city>
        <state>Connecticut</state>
        <zip>06360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US088</name>
      <address>
        <city>Atlantis</city>
        <state>Florida</state>
        <zip>33462</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US007</name>
      <address>
        <city>Brooksville</city>
        <state>Florida</state>
        <zip>34601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US002</name>
      <address>
        <city>Hallandale Beach</city>
        <state>Florida</state>
        <zip>33009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US140</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US216</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33137</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US110</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33165</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US172</name>
      <address>
        <city>North Palm Beach</city>
        <state>Florida</state>
        <zip>33408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US003</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US256</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US037</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US042</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US004</name>
      <address>
        <city>The Villages</city>
        <state>Florida</state>
        <zip>32162</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US048</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30331</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US046</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US217</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US111</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US095</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US116</name>
      <address>
        <city>Newton</city>
        <state>Massachusetts</state>
        <zip>02459</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US174</name>
      <address>
        <city>Quincy</city>
        <state>Massachusetts</state>
        <zip>02169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US144</name>
      <address>
        <city>Hattiesburg</city>
        <state>Mississippi</state>
        <zip>39401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US094</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US135</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US197</name>
      <address>
        <city>Lawrenceville</city>
        <state>New Jersey</state>
        <zip>08648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US057</name>
      <address>
        <city>Manchester</city>
        <state>New Jersey</state>
        <zip>08759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US215</name>
      <address>
        <city>Mount Arlington</city>
        <state>New Jersey</state>
        <zip>07856</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US209</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08755</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US036</name>
      <address>
        <city>West Long Branch</city>
        <state>New Jersey</state>
        <zip>07764</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US001</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US049</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US097</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US177</name>
      <address>
        <city>New Windsor</city>
        <state>New York</state>
        <zip>12553</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US142</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US044</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US150</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US185</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28270</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US113</name>
      <address>
        <city>Beachwood</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US136</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US008</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US119</name>
      <address>
        <city>Shaker Heights</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US134</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US169</name>
      <address>
        <city>Media</city>
        <state>Pennsylvania</state>
        <zip>19063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US187</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US162</name>
      <address>
        <city>Plains</city>
        <state>Pennsylvania</state>
        <zip>18075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US148</name>
      <address>
        <city>Willow Grove</city>
        <state>Pennsylvania</state>
        <zip>19001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US115</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US043</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US143</name>
      <address>
        <city>Orem</city>
        <state>Utah</state>
        <zip>84058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US149</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US170</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AR130</name>
      <address>
        <city>La Plata</city>
        <state>Buenos Aires</state>
        <zip>A1902AJU</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AR041</name>
      <address>
        <city>La Plata</city>
        <state>Buenos Aires</state>
        <zip>B1900BOM</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AR101</name>
      <address>
        <city>Buenos Aires</city>
        <zip>B1828CKR</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AR060</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1199ABB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AR084</name>
      <address>
        <city>Ciudad Autónoma de Buenos Aire</city>
        <zip>C1012AAR</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AR027</name>
      <address>
        <city>Ciudad Autónoma de Buenos Aire</city>
        <zip>C1058AAJ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AR012</name>
      <address>
        <city>Ciudad Autónoma de Buenos Aire</city>
        <zip>C1111AAL</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AR160</name>
      <address>
        <city>Ciudad Autónoma de Buenos Aire</city>
        <zip>C1117ABH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AR040</name>
      <address>
        <city>Ciudad Autónoma de Buenos Aire</city>
        <zip>C1405BCK</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AR028</name>
      <address>
        <city>Ciudad Autónoma de Buenos Aire</city>
        <zip>C1406BOA</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AR081</name>
      <address>
        <city>Ciudad Autónoma de Buenos Aire</city>
        <zip>C1425AHQ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AR035</name>
      <address>
        <city>Ciudad Autónoma de Buenos Aire</city>
        <zip>C1428AQK</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AR051</name>
      <address>
        <city>Cordoba</city>
        <zip>X5000DCE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AR137</name>
      <address>
        <city>Cordoba</city>
        <zip>X5000FJF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AR210</name>
      <address>
        <city>Mendoza</city>
        <zip>M5501ACP</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AR219</name>
      <address>
        <city>Mendoza</city>
        <zip>M5502AHV</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AR059</name>
      <address>
        <city>Santiago del Estero</city>
        <zip>G4200DND</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AU227</name>
      <address>
        <city>Caulfield</city>
        <zip>VIC3162</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AU079</name>
      <address>
        <city>Chermside</city>
        <zip>QLD 4032</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AU032</name>
      <address>
        <city>Heidelberg West</city>
        <zip>VIC 3081</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AU062</name>
      <address>
        <city>Herston</city>
        <zip>QLD 4209</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AU011</name>
      <address>
        <city>Hornsby</city>
        <zip>NSW 2077</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AU138</name>
      <address>
        <city>West Perth</city>
        <zip>WA 6005</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BU125</name>
      <address>
        <city>Ruse</city>
        <zip>7003</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BU131</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BU198</name>
      <address>
        <city>Sofia</city>
        <zip>1632</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BU073</name>
      <address>
        <city>Varna</city>
        <zip>9000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CA151</name>
      <address>
        <city>Medicine Hat</city>
        <state>Alberta</state>
        <zip>T1B4E7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CA120</name>
      <address>
        <city>Kamloops</city>
        <state>British Columbia</state>
        <zip>V2C 1K7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CA054</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 1Z9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CA188</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 4N7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CA186</name>
      <address>
        <city>Penticton</city>
        <state>British Columbia</state>
        <zip>V2A 5C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CA141</name>
      <address>
        <city>West Vancouver</city>
        <state>British Columbia</state>
        <zip>V7T 2Z3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CA147</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 5G8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CA196</name>
      <address>
        <city>North York</city>
        <state>Ontario</state>
        <zip>M3B 2S7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CA237</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4G 0A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CA236</name>
      <address>
        <city>Gatineau</city>
        <state>Quebec</state>
        <zip>J8T8JI</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH212</name>
      <address>
        <city>Antofagasta</city>
        <state>II Región</state>
        <zip>1270244</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH076</name>
      <address>
        <city>Santiago</city>
        <state>Region Metropolitana</state>
        <zip>7560356</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH061</name>
      <address>
        <city>Santiago</city>
        <state>Región Metropolitana</state>
        <zip>7510186</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH075</name>
      <address>
        <city>Santiago</city>
        <state>Región Metropolitana</state>
        <zip>7520338</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CR069</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CR122</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CR068</name>
      <address>
        <city>Zagreb</city>
        <zip>10090</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CR070</name>
      <address>
        <city>Zagreb</city>
        <zip>10090</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CR083</name>
      <address>
        <city>Zagreb</city>
        <zip>10090</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CZ128</name>
      <address>
        <city>Praha 10</city>
        <zip>100 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CZ207</name>
      <address>
        <city>Praha 10</city>
        <zip>109 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CZ132</name>
      <address>
        <city>Praha 2</city>
        <zip>120 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CZ129</name>
      <address>
        <city>Praha 6</city>
        <zip>160 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CZ161</name>
      <address>
        <city>Rychnov nad Kneznou</city>
        <zip>516 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FR231</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FR182</name>
      <address>
        <city>Marseille Cedex 5</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FR221</name>
      <address>
        <city>Paris Cedex</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FR202</name>
      <address>
        <city>Villeurbanne</city>
        <zip>69 100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GE206</name>
      <address>
        <city>Bad Homburg</city>
        <zip>61348</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GE091</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GE071</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GE139</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GE230</name>
      <address>
        <city>Cologne</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GE252</name>
      <address>
        <city>Ellwangen</city>
        <zip>73479</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GE180</name>
      <address>
        <city>Leipzig</city>
        <zip>04107</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GE228</name>
      <address>
        <city>Mannheim</city>
        <zip>68165</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GE017</name>
      <address>
        <city>Munchen</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GE157</name>
      <address>
        <city>Nürnberg</city>
        <zip>90402</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GE098</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GE251</name>
      <address>
        <city>Westerstede</city>
        <zip>26655</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IT053</name>
      <address>
        <city>Brescia</city>
        <zip>25125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IT124</name>
      <address>
        <city>Cefalù</city>
        <zip>90015</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IT030</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IT103</name>
      <address>
        <city>Perugia</city>
        <zip>06156</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IT072</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IT183</name>
      <address>
        <city>Roma</city>
        <zip>00179</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IT029</name>
      <address>
        <city>Roma</city>
        <zip>00189</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IT175</name>
      <address>
        <city>Rome</city>
        <zip>00185</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IT085</name>
      <address>
        <city>Torino</city>
        <zip>10 126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SK066</name>
      <address>
        <city>Busan</city>
        <zip>49201</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SK067</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SK190</name>
      <address>
        <city>Seoul</city>
        <zip>07061</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PO013</name>
      <address>
        <city>Bialystok</city>
        <zip>15-756</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PO024</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-080</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PO010</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-796</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PO107</name>
      <address>
        <city>Katowice</city>
        <zip>40-123</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PO092</name>
      <address>
        <city>Katowice</city>
        <zip>40-749</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PO023</name>
      <address>
        <city>Krakow</city>
        <zip>30-349</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PO025</name>
      <address>
        <city>Krakow</city>
        <zip>35-505</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PO009</name>
      <address>
        <city>Poznan</city>
        <zip>61-853</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PO014</name>
      <address>
        <city>Szczecin</city>
        <zip>70-111</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PO074</name>
      <address>
        <city>Warszawa</city>
        <zip>01-697</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SE164</name>
      <address>
        <city>Belgrade</city>
        <zip>11 000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SE090</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SE166</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SE193</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SE155</name>
      <address>
        <city>Kragujevac</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SE031</name>
      <address>
        <city>Novi Knezevac</city>
        <zip>23330</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SE165</name>
      <address>
        <city>Vrsac</city>
        <zip>26300</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SI052</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SI026</name>
      <address>
        <city>Singapore</city>
        <zip>308433</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SL056</name>
      <address>
        <city>Banska Bystrica</city>
        <zip>97404</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SL192</name>
      <address>
        <city>Bratislava</city>
        <zip>820 07</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SL200</name>
      <address>
        <city>Dubnica nad Váhom</city>
        <zip>01841</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SL191</name>
      <address>
        <city>Kosice</city>
        <zip>040 17</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SL078</name>
      <address>
        <city>Krompachy</city>
        <zip>05342</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SL077</name>
      <address>
        <city>Svidnik</city>
        <zip>08901</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SP249</name>
      <address>
        <city>Alicante</city>
        <zip>03690</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SP176</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SP022</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SP021</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SP250</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SP019</name>
      <address>
        <city>Ceuta</city>
        <zip>51003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SP194</name>
      <address>
        <city>Donostia</city>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SP222</name>
      <address>
        <city>Getxo</city>
        <zip>48993</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SP018</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SP093</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SP184</name>
      <address>
        <city>Sant Cugat del Vallès</city>
        <zip>08190</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SP020</name>
      <address>
        <city>Terrassa</city>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TA065</name>
      <address>
        <city>Kaohsiung</city>
        <zip>833</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TA086</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TA121</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UK063</name>
      <address>
        <city>Bath</city>
        <zip>BA1 3NG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UK038</name>
      <address>
        <city>Blackpool</city>
        <zip>FY2 0JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UK233</name>
      <address>
        <city>Cambridge</city>
        <zip>CB21 5EF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UK033</name>
      <address>
        <city>Cannock</city>
        <zip>WS11 0BN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UK211</name>
      <address>
        <city>Epping</city>
        <zip>CM16 6TN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UK234</name>
      <address>
        <city>Guildford</city>
        <zip>GU2 7YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UK055</name>
      <address>
        <city>Leeds</city>
        <zip>LS10 1DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UK039</name>
      <address>
        <city>London</city>
        <zip>W1G 9JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UK034</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9NQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UK229</name>
      <address>
        <city>Norwich</city>
        <zip>NR2 3TD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UK087</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UK235</name>
      <address>
        <city>Plymouth</city>
        <zip>PL5 8BT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UK100</name>
      <address>
        <city>Sheffield</city>
        <zip>S5 7JT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UK064</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UK152</name>
      <address>
        <city>Southampton</city>
        <zip>SO30 3JB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UK153</name>
      <address>
        <city>Swindon</city>
        <zip>SN3 6BW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UK154</name>
      <address>
        <city>Warrington</city>
        <zip>WA22 8WA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Croatia</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Serbia</country>
    <country>Singapore</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>October 22, 2015</study_first_submitted>
  <study_first_submitted_qc>October 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2015</study_first_posted>
  <results_first_submitted>September 30, 2018</results_first_submitted>
  <results_first_submitted_qc>November 8, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 5, 2018</results_first_posted>
  <last_update_submitted>November 8, 2018</last_update_submitted>
  <last_update_submitted_qc>November 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's disease</keyword>
  <keyword>RVT-101</keyword>
  <keyword>donepezil</keyword>
  <keyword>intepirdine</keyword>
  <keyword>dementia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol: Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 13, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/34/NCT02585934/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan: Statistical Analysis Plan Document</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 9, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/34/NCT02585934/SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan: Statistical Analysis Plan Addendum Document</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 19, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/34/NCT02585934/SAP_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>2173 participants signed consent and were screened for participation. Of these, 1470 entered a 3-week single-blind placebo run-in period with treatment with placebo qd + stable dose of donepezil 5 or 10 mg qd. There was an overlap between the participants from the run-in period and the participants that were randomized during the treatment period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>RVT-101</title>
          <description>RVT-101 adjunct to 5 mg or 10 mg donepezil
RVT-101: once daily, oral, 35 mg tablets for up to 27 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo adjunct to 5 mg or 10 mg donepezil
Placebo: once daily, oral, pill manufactured to match RVT-101 35 mg tablet for up to 27 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="661"/>
                <participants group_id="P2" count="654"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="656"/>
                <participants group_id="P2" count="651"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Intent to Treat (ITT)</title>
              <participants_list>
                <participants group_id="P1" count="643"/>
                <participants group_id="P2" count="633"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Per Protocol (PP)</title>
              <participants_list>
                <participants group_id="P1" count="603"/>
                <participants group_id="P2" count="582"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="592"/>
                <participants group_id="P2" count="581"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="73"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Caregiver Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Termination</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Another Reason</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>ITT population</population>
      <group_list>
        <group group_id="B1">
          <title>RVT-101</title>
          <description>RVT-101 adjunct to 5 mg or 10 mg donepezil
RVT-101: once daily, oral, 35 mg tablets for up to 27 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo adjunct to 5 mg or 10 mg donepezil
Placebo: once daily, oral, pill manufactured to match RVT-101 35 mg tablet for up to 27 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="643"/>
            <count group_id="B2" value="633"/>
            <count group_id="B3" value="1276"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="643"/>
                    <count group_id="B2" value="633"/>
                    <count group_id="B3" value="1276"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.7" lower_limit="50" upper_limit="85"/>
                    <measurement group_id="B2" value="72.5" lower_limit="50" upper_limit="86"/>
                    <measurement group_id="B3" value="72.6" lower_limit="50" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&lt; 74 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="643"/>
                    <count group_id="B2" value="633"/>
                    <count group_id="B3" value="1276"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="309"/>
                    <measurement group_id="B2" value="312"/>
                    <measurement group_id="B3" value="621"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;/= 74 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="643"/>
                    <count group_id="B2" value="633"/>
                    <count group_id="B3" value="1276"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="334"/>
                    <measurement group_id="B2" value="321"/>
                    <measurement group_id="B3" value="655"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt; 65 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="643"/>
                    <count group_id="B2" value="633"/>
                    <count group_id="B3" value="1276"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;/=65 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="643"/>
                    <count group_id="B2" value="633"/>
                    <count group_id="B3" value="1276"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="545"/>
                    <measurement group_id="B2" value="536"/>
                    <measurement group_id="B3" value="1081"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="643"/>
                    <count group_id="B2" value="633"/>
                    <count group_id="B3" value="1276"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="386"/>
                    <measurement group_id="B2" value="394"/>
                    <measurement group_id="B3" value="780"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="257"/>
                    <measurement group_id="B2" value="239"/>
                    <measurement group_id="B3" value="496"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="643"/>
                    <count group_id="B2" value="633"/>
                    <count group_id="B3" value="1276"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="228"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="518"/>
                    <measurement group_id="B2" value="519"/>
                    <measurement group_id="B3" value="1037"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="643"/>
                    <count group_id="B2" value="633"/>
                    <count group_id="B3" value="1276"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="595"/>
                    <measurement group_id="B2" value="592"/>
                    <measurement group_id="B3" value="1187"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Others</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Applicable</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <population>Data was missing for one subject</population>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="642"/>
                    <count group_id="B2" value="633"/>
                    <count group_id="B3" value="1275"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.4" lower_limit="17.2" upper_limit="56.3"/>
                    <measurement group_id="B2" value="26.5" lower_limit="15.2" upper_limit="45.3"/>
                    <measurement group_id="B3" value="26.4" lower_limit="15.2" upper_limit="56.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Alzheimer's Disease Assessment Scale - Cognitive Subscale 11 Items (ADAS-Cog-11) Score Change From Baseline to Week 24</title>
        <description>The 11-item ADAS-Cog assesses a range of cognitive abilities including memory, comprehension, orientation in time and place, and spontaneous speech. The ADAS-Cog-11 total score range is from 0 to 70, with a higher score indicating more severe cognitive impairment.</description>
        <time_frame>Baseline, 24 weeks</time_frame>
        <population>ITT Population with data at both timepoints.</population>
        <group_list>
          <group group_id="O1">
            <title>RVT-101</title>
            <description>RVT-101 adjunct to 5 mg or 10 mg donepezil
RVT-101: once daily, oral, 35 mg tablets</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo adjunct to 5 mg or 10 mg donepezil
Placebo: once daily, oral, pill manufactured to match RVT-101 35 mg tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Alzheimer's Disease Assessment Scale - Cognitive Subscale 11 Items (ADAS-Cog-11) Score Change From Baseline to Week 24</title>
          <description>The 11-item ADAS-Cog assesses a range of cognitive abilities including memory, comprehension, orientation in time and place, and spontaneous speech. The ADAS-Cog-11 total score range is from 0 to 70, with a higher score indicating more severe cognitive impairment.</description>
          <population>ITT Population with data at both timepoints.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="584"/>
                <count group_id="O2" value="577"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.39" spread="0.211"/>
                    <measurement group_id="O2" value="0.75" spread="0.213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2249</p_value>
            <p_value_desc>the threshold for statistical significance was p=0.05</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Statistical Method: Mixed model for repeated measures</method_desc>
            <param_type>least square mean difference</param_type>
            <param_value>-0.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.95</ci_lower_limit>
            <ci_upper_limit>0.22</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) Score Change From Baseline to Week 24</title>
        <description>The ADCS-ADL scale measures functional impairment in terms of activities of daily living. The score ranges from 0 to 78. The lower the score, the greater the impairment; higher scores indicate better (more desirable) function</description>
        <time_frame>Baseline, 24 weeks</time_frame>
        <population>ITT Population with data at both endpoints</population>
        <group_list>
          <group group_id="O1">
            <title>RVT-101</title>
            <description>RVT-101 adjunct to 5 mg or 10 mg donepezil
RVT-101: once daily, oral, 35 mg tablets</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo adjunct to 5 mg or 10 mg donepezil
Placebo: once daily, oral, pill manufactured to match RVT-101 35 mg tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) Score Change From Baseline to Week 24</title>
          <description>The ADCS-ADL scale measures functional impairment in terms of activities of daily living. The score ranges from 0 to 78. The lower the score, the greater the impairment; higher scores indicate better (more desirable) function</description>
          <population>ITT Population with data at both endpoints</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="588"/>
                <count group_id="O2" value="575"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.06" spread="0.289"/>
                    <measurement group_id="O2" value="-0.97" spread="0.293"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8260</p_value>
            <p_value_desc>the threshold for statistical significance was p=0.05</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Statistical Method: Mixed model for repeated measures</method_desc>
            <param_type>least square mean difference</param_type>
            <param_value>-0.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.90</ci_lower_limit>
            <ci_upper_limit>0.72</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impression of Change - Plus Caregiver Interview (CIBIC+) Score at Week 24</title>
        <description>The CIBIC+ assessment measures the global functioning of the subject. The CIBIC+ is scored as a seven-point categorical rating, ranging from a score of 1 (indicating &quot;very much improved&quot;), to a score of 4 (indicating &quot;no change&quot;), or to a score of 7 (indicating &quot;very much worse.&quot;) Lower CIBIC+ scores indicate better (more desirable) function</description>
        <time_frame>24 weeks</time_frame>
        <population>ITT population at the Week 24 timepoint</population>
        <group_list>
          <group group_id="O1">
            <title>RVT-101</title>
            <description>RVT-101 adjunct to 5 mg or 10 mg donepezil
RVT-101: once daily, oral, 35 mg tablets</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo adjunct to 5 mg or 10 mg donepezil
Placebo: once daily, oral, pill manufactured to match RVT-101 35 mg tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impression of Change - Plus Caregiver Interview (CIBIC+) Score at Week 24</title>
          <description>The CIBIC+ assessment measures the global functioning of the subject. The CIBIC+ is scored as a seven-point categorical rating, ranging from a score of 1 (indicating &quot;very much improved&quot;), to a score of 4 (indicating &quot;no change&quot;), or to a score of 7 (indicating &quot;very much worse.&quot;) Lower CIBIC+ scores indicate better (more desirable) function</description>
          <population>ITT population at the Week 24 timepoint</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="577"/>
                <count group_id="O2" value="568"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.18" spread="0.037"/>
                    <measurement group_id="O2" value="4.30" spread="0.037"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0234</p_value>
            <p_value_desc>the threshold for statistical significance was p=0.05</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Statistical Method: Mixed model for repeated measures</method_desc>
            <param_type>least square mean difference</param_type>
            <param_value>-0.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.22</ci_lower_limit>
            <ci_upper_limit>-0.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Dependence Scale (DS) Score Change From Baseline to Week 24</title>
        <description>The DS measures the amount of assistance patients with dementia require in performing daily activities. The scale consists of 13 items, representing a range of severity from mild to severe levels of dependency. The score range is from 0 to 15 with higher scores indicating greater dependency.</description>
        <time_frame>Baseline, 24 weeks</time_frame>
        <population>ITT population at both timepoints</population>
        <group_list>
          <group group_id="O1">
            <title>RVT-101</title>
            <description>RVT-101 adjunct to 5 mg or 10 mg donepezil
RVT-101: once daily, oral, 35 mg tablets</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo adjunct to 5 mg or 10 mg donepezil
Placebo: once daily, oral, pill manufactured to match RVT-101 35 mg tablet</description>
          </group>
        </group_list>
        <measure>
          <title>The Dependence Scale (DS) Score Change From Baseline to Week 24</title>
          <description>The DS measures the amount of assistance patients with dementia require in performing daily activities. The scale consists of 13 items, representing a range of severity from mild to severe levels of dependency. The score range is from 0 to 15 with higher scores indicating greater dependency.</description>
          <population>ITT population at both timepoints</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="580"/>
                <count group_id="O2" value="568"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30" spread="0.070"/>
                    <measurement group_id="O2" value="0.17" spread="0.071"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2096</p_value>
            <p_value_desc>the threshold for statistical significance was p=0.05</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Statistical Method: Mixed model for repeated measures</method_desc>
            <param_type>least square mean difference</param_type>
            <param_value>0.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.07</ci_lower_limit>
            <ci_upper_limit>0.32</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neuropsychiatric Inventory (NPI) Score Change From Baseline to Week 24</title>
        <description>The NPI is a behavior rating scale composed of a 12-item structured interview of the caregiver that is scored from 0 to 144 (the higher the score, the greater the psychiatric disturbance). It assesses 12 behavioral disturbances occurring in dementia patients: delusions, hallucinations, agitation, dysphoria, anxiety, apathy, irritability, euphoria, disinhibition, aberrant motor activity, night-time behavior disturbances, and eating disturbances. Both the frequency and the severity of each behavior are determined.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>ITT Population at both timepoints</population>
        <group_list>
          <group group_id="O1">
            <title>RVT-101</title>
            <description>RVT-101 adjunct to 5 mg or 10 mg donepezil
RVT-101: once daily, oral, 35 mg tablets</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo adjunct to 5 mg or 10 mg donepezil
Placebo: once daily, oral, pill manufactured to match RVT-101 35 mg tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Neuropsychiatric Inventory (NPI) Score Change From Baseline to Week 24</title>
          <description>The NPI is a behavior rating scale composed of a 12-item structured interview of the caregiver that is scored from 0 to 144 (the higher the score, the greater the psychiatric disturbance). It assesses 12 behavioral disturbances occurring in dementia patients: delusions, hallucinations, agitation, dysphoria, anxiety, apathy, irritability, euphoria, disinhibition, aberrant motor activity, night-time behavior disturbances, and eating disturbances. Both the frequency and the severity of each behavior are determined.</description>
          <population>ITT Population at both timepoints</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="583"/>
                <count group_id="O2" value="570"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="0.339"/>
                    <measurement group_id="O2" value="0.06" spread="0.344"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7650</p_value>
            <p_value_desc>the threshold for statistical significance was p=0.05</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Statistical Method: Mixed model for repeated measures</method_desc>
            <param_type>least square mean difference</param_type>
            <param_value>-0.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.09</ci_lower_limit>
            <ci_upper_limit>0.80</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ADAS-Cog-13 Score Change From Baseline to Week 24</title>
        <description>13-item ADAS-Cog assesses a range of cognitive abilities including memory, comprehension, orientation in time and place, and spontaneous speech. Most items are evaluated by tests, but some are dependent on clinician ratings on a 5-point scale. The ADAS-Cog-13 is the ADAS-Cog-11 with 2 additional items: delayed word recall and total digit cancellation. Scores for the ADAS-Cog-13 range from 0 to 85 with higher scores indicating greater dysfunction.</description>
        <time_frame>Baseline, 24 weeks</time_frame>
        <population>ITT at both timepoints</population>
        <group_list>
          <group group_id="O1">
            <title>RVT-101</title>
            <description>RVT-101 adjunct to 5 mg or 10 mg donepezil
RVT-101: once daily, oral, 35 mg tablets</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo adjunct to 5 mg or 10 mg donepezil
Placebo: once daily, oral, pill manufactured to match RVT-101 35 mg tablet</description>
          </group>
        </group_list>
        <measure>
          <title>ADAS-Cog-13 Score Change From Baseline to Week 24</title>
          <description>13-item ADAS-Cog assesses a range of cognitive abilities including memory, comprehension, orientation in time and place, and spontaneous speech. Most items are evaluated by tests, but some are dependent on clinician ratings on a 5-point scale. The ADAS-Cog-13 is the ADAS-Cog-11 with 2 additional items: delayed word recall and total digit cancellation. Scores for the ADAS-Cog-13 range from 0 to 85 with higher scores indicating greater dysfunction.</description>
          <population>ITT at both timepoints</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="583"/>
                <count group_id="O2" value="576"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" spread="0.233"/>
                    <measurement group_id="O2" value="0.64" spread="0.236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2472</p_value>
            <p_value_desc>the threshold for statistical significance was p=0.05</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Statistical Method: Mixed model for repeated measures</method_desc>
            <param_type>least square mean difference</param_type>
            <param_value>-0.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.03</ci_lower_limit>
            <ci_upper_limit>0.27</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurement of Concentrations of RVT-101 (Intepirdine) in Plasma</title>
        <description>Measurement collected at timepoints Week 6, Week 12, Week 18, and Week 24</description>
        <time_frame>Week 6, Week 12, Week 18, Week 24</time_frame>
        <population>PK population at specified timepoints: Week 6, Week 12, Week 18, and Week 24</population>
        <group_list>
          <group group_id="O1">
            <title>RVT-101</title>
            <description>RVT-101 adjunct to 5 mg or 10 mg donepezil
RVT-101: once daily, oral, 35 mg tablets for up to 27 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of Concentrations of RVT-101 (Intepirdine) in Plasma</title>
          <description>Measurement collected at timepoints Week 6, Week 12, Week 18, and Week 24</description>
          <population>PK population at specified timepoints: Week 6, Week 12, Week 18, and Week 24</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="656"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Summary Statistics at Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="563"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="201.11" lower_limit="191.88" upper_limit="210.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Summary Statistics at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="579"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="170.95" lower_limit="164.40" upper_limit="177.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Summary Statistics at Week 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="454"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="198.69" lower_limit="189.36" upper_limit="208.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Summary Statistics at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="562"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="193.36" lower_limit="184.60" upper_limit="202.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Screening through post treatment (up to 33 weeks)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>RVT-101 Treatment</title>
          <description>RVT-101 adjunct to 5 mg or 10 mg donepezil
RVT-101: once daily, oral, 35 mg tablets for up to 27 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo Treatment</title>
          <description>Placebo adjunct to 5 mg or 10 mg donepezil
Placebo: once daily, oral, pill manufactured to match RVT-101 35 mg tablet for up to 27 weeks</description>
        </group>
        <group group_id="E3">
          <title>Screening Period</title>
          <description>Participants screened (0-4 weeks) prior to entering to the first dose of single-blind study medication (ie, prior to the Run-In period)</description>
        </group>
        <group group_id="E4">
          <title>Run-In Period</title>
          <description>Placebo adjunct to 5 mg or 10 mg donepezil
Placebo: once daily, oral, pill manufactured to match RVT-101 35 mg tablet (for 3 weeks)</description>
        </group>
        <group group_id="E5">
          <title>RVT-101 Post-Treatment</title>
          <description>Subjects reported adverse events after completing the treatment period.
The Post-Treatment period - defined as up to 30 days post-last-dose</description>
        </group>
        <group group_id="E6">
          <title>Placebo Post-Treatment</title>
          <description>Subjects reported adverse events after completing the treatment period.
The Post-Treatment period - defined as up to 30 days post-last-dose</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="651"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Mitral valve prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Sinus node dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Inner ear disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Vertigo positonal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Duodenal vascular ectasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Volvulus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Infected bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="651"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Stoma obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Pubis fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Acoustic neuroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Hepatocellular carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Hypoxic-ischaemic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Mood altered</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Somatic symptom disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="651"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Pneumothorax spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Poor peripheral circulation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="191" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="166" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="651"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2173"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1470"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="656"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="651"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>All proposed manuscripts, publications or abstracts must be reviewed and approved by the Sponsor 60 days prior to submission for publication. All confidential information identified by the Sponsor must be deleted prior to submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ilise Lombardo, MD</name_or_title>
      <organization>Axovant Sciences, Inc.</organization>
      <phone>646-822-8626</phone>
      <email>ilise.lombardo@axovant.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

